Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma

被引：5
|
作者：
Gao, Jianjun
Karam, Jose A.
Wood, Christopher G.
Matin, Surena
Ahrar, Kamran
Jonasch, Eric
Tannir, Nizar
Campell, Matthew
Ng, Chaan S.
Slack, Rebecca S.
Rao, Priya
Allison, James P.
Blando, Jorge M.
Vence, Luis M.
Basu, Sreyashi
Zhao, Hao
Chen, Tenghui
Chen, Hong
Sharma, Padmanee
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-CT083
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT083
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
    Valerie Glutsch
    Hermann Kneitz
    Anja Gesierich
    Matthias Goebeler
    Sebastian Haferkamp
    Jürgen C. Becker
    Selma Ugurel
    Bastian Schilling
    Cancer Immunology, Immunotherapy, 2021, 70 : 2087 - 2093
  • [32] Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma
    Teishima, Jun
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 752 - 753
  • [33] Impact of treatment line on outcomes with salvage ipilimumab plus nivolumab in metastatic renal cell carcinoma (mRCC).
    Kotecha, Ritesh
    Lee, Chung-Han
    Knezevic, Andrea
    Shah, Neil J.
    Carlo, Maria Isabel
    Feldman, Darren R.
    Patil, Sujata
    Motzer, Robert J.
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma
    Yamashita, Shimpei
    Hamamoto, Shuzo
    Furukawa, Junya
    Fujita, Kazutoshi
    Takahashi, Masayuki
    Miyake, Makito
    Ito, Noriyuki
    Iwamoto, Hideto
    Kohjimoto, Yasuo
    Hara, Isao
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [35] Nivolumab Plus Ipilimumab vs Nivolumab Alone in Advanced Cancers Other Than Melanoma A Meta-Analysis
    Serritella, Anthony V.
    Shenoy, Niraj K.
    JAMA ONCOLOGY, 2023, 9 (10) : 1441 - 1446
  • [36] CLINICAL IMPLICATIONS AND PREDICTIVE FACTORS OF PRIMARY RESISTANCE TO NIVOLUMAB PLUS IPILIMUMAB THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Numakura, Kazuyuki
    Hatakeyama, Shingo
    Sekine, Yuya
    Yumina, Muto
    Kobayashi, Mizuki
    Kashima, Soki
    Yamamoto, Ryohei
    Nara, Taketoshi
    Saito, Mitsuru
    Narita, Shintaro
    Ohyama, Chikara
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2023, 209 : E371 - E372
  • [37] Nivolumab plus Ipilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma A Nonrandomized Clinical Trial
    Grimm, Marc-Oliver
    Schostak, Martin
    Gruen, Christine Barbara
    Loidl, Wolfgang
    Pichler, Martin
    Zimmermann, Uwe
    Schmitz-Draeger, Bernd
    Steiner, Thomas
    Roghmann, Florian
    Niegisch, Guenter
    Bolenz, Christian
    Schmitz, Marc
    Baretton, Gustavo
    Leucht, Katharina
    Schumacher, Ulrike
    Foller, Susan
    Zengerling, Friedemann
    Meran, Johannes
    JAMA ONCOLOGY, 2024, 10 (06) : 755 - 764
  • [38] Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2015, 57 (1483): : 168 - 168
  • [39] Pembrolizumab plus lenvatinib vs nivolumab plus cabozantinib in patients with metastatic renal cell carcinoma: A matching adjusted indirect comparison (MAIC).
    Rane, Pratik
    Walton, Laura
    Schmidinger, Manuela
    Peer, Avivit
    Mt-Isa, Shahrul
    Burgents, Joseph E.
    Sundaram, Murali
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 399 - 399
  • [40] Clinical activity of ipilimumab plus nivolumab (Ipi/Nivo) in patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC).
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Gul, Anita
    Allman, Kimberly D.
    Ball, Jessica
    Wood, Laura S.
    Garcia, Jorge A.
    VonMerveldt, Dendra
    Hammers, Hans J.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345